Overview

A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and safety of AMG 102 in patients with Advanced Renal Cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Monoclonal
Dihydrotachysterol
Rilotumumab